Agenus Announces Data from Phase II Study of BOT+BAL in Combination with agent-797 in PD-1 Refractory Gastroesophageal Cancer to be Presented at AACR 2026

AI Briefing

• – Agenus to present Phase II study data on cancer treatment
• – BOT+BAL combination therapy in PD-1 refractory Gastroesophageal Cancer
• – AACR Annual Meeting 2026 to be held in San Diego, CA